ViennaLab Diagnostics and its partners secured funding for phase 2 of the prestigious oncNGS project.
ViennaLab Diagnostics partnered together with Euformatics and Oncompass Medicine and progressed to the phase 2 to design a state-of-the-art solution which aims to revolutionize the field of liquid biopsy and cancer detection.
Phase 2 will last 12 months, during which, we will apply our expertise to develop a non-invasive Pan-cancer cfDNA test to profile the tumor landscape and predict the best personalized treatment for every patient.
For more information, follow the link to Media Centre announcement. Please click here for the official Press Release.